The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | Venetoclax with bortezomib/dexamethasone: phase 3 BELLINI results in R/R myeloma
Shaji Kumar from the Mayo Clinic, Rochester, MN, discusses the data he presented as a late-breaking abstract at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands. Dr Kumar presents the results of the Phase 3 trial investigating venetoclax in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. This press briefing was recorded at the 24th Congress of the EHA 2019, held in Amsterdam, Netherlands.
